Gangguan Panik

01Pathophysiology

Panic disorder arises from a dysregulated fear circuit centered on the amygdala, locus coeruleus, and hypothalamus. The locus coeruleus, the brain's primary noradrenergic nucleus, becomes hyperactive and fires inappropriately, triggering a "false alarm" sympathetic surge even in the absence of real danger. This is the direct pathophysiological basis for the PPDGJ III criterion that attacks occur "in situations where objectively there is no danger."

The autonomic nervous system activation explains nearly every symptom the patient experiences. Catecholamine release causes tachycardia and palpitations. Sympathetic stimulation of sweat glands produces diaphoresis. Hyperventilation from increased respiratory drive leads to hypocapnia and respiratory alkalosis, which causes perioral and acral tingling, dizziness, and a sensation of derealization. Chest pain results from intercostal muscle tension and esophageal spasm during the sympathetic storm.

A critical concept to understand is anticipatory anxiety ("anxietas antisipatorik" in PPDGJ III). After experiencing several attacks, the patient develops a conditioned fear response: they begin to fear the next attack itself. This creates a self-perpetuating cycle where the fear of having a panic attack raises baseline anxiety, which lowers the threshold for triggering another attack. This anticipatory component is explicitly acknowledged in PPDGJ III as a common finding between episodes, even though the diagnostic criteria require that the patient be relatively free of anxiety symptoms between attacks.

The unpredictability of attacks is a hallmark feature and a key discriminator from phobic disorders. In phobic anxiety disorders, attacks are triggered by identifiable stimuli (e.g., crowds, heights, specific objects). In panic disorder, the attacks are not limited to known or predictable situations, which is why PPDGJ III explicitly requires this feature for diagnosis.

02Classification and Clinical Manifestation

Severity

Symptom Domains

PPDGJ III Diagnostic Criteria

03Diagnostic Workup

The best initial diagnostic step is a thorough clinical interview applying the PPDGJ III criteria. There is no laboratory test or imaging study that confirms panic disorder. The diagnosis is entirely clinical. However, because panic attacks mimic many organic conditions (particularly cardiac and endocrine emergencies), the workup must systematically exclude these before the diagnosis is established.

The most important organic mimics to rule out are hyperthyroidism (check TSH), pheochromocytoma (if attacks are accompanied by hypertension, check 24-hour urine metanephrines and catecholamines), cardiac arrhythmia (ECG, Holter monitor if episodes are recurrent), and substance-induced anxiety (urine drug screen, caffeine intake history).

The gold standard for diagnosis is fulfillment of the PPDGJ III clinical criteria. On the exam, the key recognition pattern is a young patient (usually female) presenting to the emergency department with acute chest pain, shortness of breath, and tachycardia, with a completely normal cardiac and laboratory workup, who reports the episode peaked within minutes and resolved spontaneously. The question will often note a "normal ECG" and "normal troponin" to signal that you should be thinking about panic disorder rather than acute coronary syndrome.

One point that is heavily tested: PPDGJ III requires that the attacks must occur over approximately one month with multiple severe episodes. A single isolated panic attack does not meet criteria for panic disorder.

04Management and Treatment

Acute stabilization focuses on terminating the panic attack and providing reassurance. Benzodiazepines are the most effective agents for rapid symptom relief. Alprazolam is the most commonly used because of its rapid onset (15 to 20 minutes orally). However, benzodiazepines carry a risk of dependence and should not be used as sole long-term therapy. On the exam, if the question asks for the "best initial treatment for an acute panic attack," the answer is a benzodiazepine.

Long-term management is where exam questions become more nuanced. The first-line long-term pharmacotherapy is an SSRI. Sertraline and escitalopram have the strongest evidence base. A critical teaching point: SSRIs take 4 to 6 weeks to reach full therapeutic effect in panic disorder. During this initial period, symptoms may transiently worsen (a phenomenon called "jitteriness syndrome"), which is why treatment is started at a low dose and titrated slowly. It is common practice to co-prescribe a short course of benzodiazepines (2 to 4 weeks) as a bridge while the SSRI takes effect.

Treatment duration for the first episode is a minimum of 12 months after achieving remission. Discontinuation should be gradual (taper over 4 to 8 weeks) to prevent withdrawal symptoms and relapse.

CBT is the first-line psychotherapy and has evidence of efficacy equal to pharmacotherapy for mild to moderate panic disorder. The combination of SSRI plus CBT is the most effective strategy overall and is preferred for moderate to severe presentations.

Contraindications and cautions:
Tricyclic antidepressants (TCAs) such as imipramine are effective but are reserved as third-line because of anticholinergic side effects, cardiac toxicity in overdose, and weight gain. MAO inhibitors are effective but rarely used due to dietary restrictions and drug interactions. In pregnancy, SSRIs (particularly sertraline) are considered the safest pharmacological option; benzodiazepines should be avoided especially near delivery due to neonatal sedation and withdrawal risk.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students get panic disorder questions wrong is by failing to recognize the PPDGJ III hierarchy rule. Panic disorder can only be diagnosed as the primary condition when phobic anxiety disorder has been excluded. If a vignette describes a patient who has panic attacks exclusively in crowded places or open spaces, the correct diagnosis is agoraphobia with panic attacks, not panic disorder. The attacks must be unpredictable and not situationally bound.

The second major trap involves the management sequence. When a question describes a patient in the emergency department during an acute attack, the answer is a benzodiazepine for immediate relief. However, when the question describes a patient who has been having recurrent attacks over the past two months and asks for the "best long-term treatment," the answer shifts to an SSRI. Students who reflexively choose benzodiazepines for every panic disorder question will lose points on the long-term management items.

A third commonly tested concept is the one-month timeframe. PPDGJ III requires several severe attacks within approximately one month. A single panic attack, no matter how severe, does not meet the diagnostic threshold. If a vignette describes only one episode, the correct approach is to monitor and reassess rather than diagnose panic disorder.

Finally, students must remember that panic disorder is a diagnosis of exclusion in the acute setting. Before labeling a patient with panic disorder, organic causes (cardiac, endocrine, substance-related, neurological) must be ruled out with appropriate testing. The exam will test whether you order the right workup before committing to a psychiatric diagnosis.

The core competency being tested is the ability to recognize the episodic, unpredictable, autonomic nature of panic attacks, correctly apply the PPDGJ III diagnostic hierarchy (excluding phobic disorders first), and sequence the management appropriately between acute and long-term phases.